Thanks to a $7 million donation from Mississauga-based Orlando Corporation, The University of Toronto Mississauga has launched an interdisciplinary centre for the development of new drugs targeting cancer and other diseases.
The focus of the new Centre for Medicinal Chemistry will be to create compounds that are purpose-built to interrupt specific biochemical processes while avoiding harm to normal cellular functions. Researchers at the centre will include Patrick Gunning of UTM’s Department of Chemical & Physical Sciences and four new principal investigators who will partner in medicinal chemistry, computational chemistry, cancer biology and stem cell biology.
Gunning’s research team designs lead compounds that have the potential to be turned into cancer-fighting drugs. In just the past five years, the Gunning team has moved four lead compounds to advanced pre-clinical trials. The great promise of this research is to dramatically reduce the time and cost of developing lead compounds, resulting in a much larger pipeline of molecules to fight many forms of cancer as well as other diseases.
This is a significant investment that will be a major research asset to our existing life sciences ecosystem and bring us closer to finding a cure for many forms of cancer and other diseases right here in Mississauga.
To read more on the story, view the article on UofT Mississauga’s website here.
Latest posts by Bonnie Brown (see all)
- U of T Mississauga launches Centre for Medicinal Chemistry - September 28, 2016
- Differentiating Mississauga’s Economy - May 10, 2016
- Mississauga’s Companies – Global Magnets In The Life Sciences Industry - July 3, 2015